Haemonetics Corporation (HAE) News
Track canonical SquawkNews coverage tagged to HAE, Haemonetics Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Haemonetics sets Nov. 5 date for Q2 FY2027 results
Haemonetics said it will publish second-quarter fiscal 2027 results on November 5, 2026.
EQUITY | Sep 30, 2026, 08:05 PM UTC
L
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strate
MNA | Sep 15, 2026, 12:33 PM UTC
L
Haemonetics maintained at Outperform by Raymond James
Raymond James maintains an Outperform rating on Haemonetics.
EQUITY | Sep 03, 2026, 06:36 PM UTC
L
Haemonetics signs CSL Plasma supply agreement, shares hit 52-week high
Haemonetics Corp. says it executed a non-exclusive supply agreement with CSL Plasma for NexSys PCS devices and Persona PLUS technology across CSL’s U.S. network, while leaving fiscal 2027 guidance unchanged.
EARNINGS | Aug 18, 2026, 05:12 PM UTC
H
AMLX jumps on Phase 3 LUCIDITY avexitide topline results
ALXN-backed ally?—No: AMLX is up about 29% after positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide, while HAE and BBWI also post gains and HD adds a 2% earnings move.
EARNINGS | Aug 18, 2026, 12:20 PM UTC
L
Haemonetics signs non-exclusive CSL Plasma supply agreement
Haemonetics says it will supply CSL Plasma with NexSys PCS devices featuring Persona PLUS technology and allow purchases of related disposables in the U.S., under a non-exclusive agreement with no minimum purchase commit
EARNINGS | Aug 18, 2026, 10:15 AM UTC
L
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est
Haemonetics (NYSE: HAE ) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.
EARNINGS | Aug 06, 2026, 10:02 AM UTC
L
HAE - Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website - Click For Rele
HAE - Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
EQUITY | Aug 06, 2026, 10:00 AM UTC
M
HAE: VASCADE MVP XL System Effective
HAE's VASCADE MVP XL System shows effectiveness
EQUITY | Aug 03, 2026, 08:15 PM UTC
L
HAE - Martin Madaus Elected to Haemonetics Board of Directors
HAE - Martin Madaus Elected to Haemonetics Board of Directors
EQUITY | Jul 28, 2026, 08:16 PM UTC
L
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
EQUITY | Jul 28, 2026, 11:29 AM UTC